SHIRAS JEWELLERS LTDBusiness Directories,Company Directories

Company Name: Corporate Name:	SHIRAS JEWELLERS LTD
Company Title:
Company Description:
Keywords to Search:
Company Address:	Mapleview Centre,BURLINGTON,ON,Canada
ZIP Code: Postal Code:	L7L
Telephone Number:	9056817557
Fax Number:
Website:
Email:
USA SIC Code(Standard Industrial Classification Code):	127630
USA SIC Description:	JEWELERS
Number of Employees:
Sales Amount:	$2.5 to 5 million
Credit History: Credit Report:	Good
Contact Person:
Remove my name

Company Directories & Business Directories

copy and paste this google map to your website or blog!

Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples:
WordPress Example, Blogger Example)

Input Form:Deal with this potential dealer,buyer,seller,supplier,manufacturer,exporter,importer

(Any information to deal,buy, sell, quote for products or service)

Previous company profile:
SHOE CLUB
SHOE CO
SHO-MOVES INC

Next company profile:
SHIRAS JEWELLERS LTD
SHIPWAY STAIRS LIMITED
SHIPWAY STAIRS LTD

Company News:

Model-informed precision dosing for alemtuzumab in paediatric and young . . .
The purpose of this study was to characterize alemtuzumab population pharmacokinetic pharmacodynamic (PK PD) and to propose individualized subcutaneous dosing schemes to achieve this optimal level for paediatric patients
Model‐informed precision dosing for alemtuzumab in paediatric and young . . .
An allometry- or body surface area-based starting dosing regimen in combination with individualized Bayesian PK estimation using concentration feedback is proposed for alemtuzumab precision dosing in children undergoing allogeneic HCT
Precision Dosing of Alemtuzumab: Population . . . - ScienceDirect
In order to support targeted precision dosing of alemtuzumab in a prospective clinical trial, we have developed a population PK (PPK) model for Bayesian adaptive control
Alemtuzumab Precision Dosing in Allogeneic Hematopoietic Cell . . .
High alemtuzumab levels at day 0 are associated with decreased rates of acute graft-versus-host disease (aGVHD) but increased rates of mixed chimerism, viral reactivation and delayed immune reconstitution
Serotherapy as Graft-Versus-Host Disease Prophylaxis in Haematopoietic . . .
Precision dosing of alemtuzumab: Population pharmacokinetic modeling in pediatric patients undergoing allogeneic hematopoietic cell transplantation for non-malignant diseases
A prospective pilot study of a novel alemtuzumab target . . . - Nature
We performed a pilot study of a novel target concentration intervention strategy to target day 0 alemtuzumab concentrations to 0 15–0 6 mcg mL Twelve patients received model-informed
Chie EMOTO | Cincinnati Childrens Hospital Medical Center, Ohio . . .
It is well known that pharmacokinetics (PK)-guided busulfan (BU) dosing increases engraftment rates and lowers hepatotoxicity in patients undergoing hematopoietic cell transplantation (HCT)
Allogeneic Hematopoietic cell Transplantation Using Alemtuzumab in . . .
Dong M, Emoto C, Fukuda T, Arnold DE, Mehta PA, Marsh RA, et al Model-informed precision dosing for alemtuzumab in paediatric and young adult patients undergoing allogeneic haematopoietic cell transplantation
Precision Dosing of Alemtuzumab: Population Pharmacokinetic Modeling in . . .
In order to support targeted precision dosing of alemtuzumab in a prospective clinical trial, we have developed a population PK (PPK) model for Bayesian adaptive control
Model-informed precision dosing for alemtuzumab in pediatric and young . . .
With the goal of identifying an optimal dosing schedule for alemtuzumab in allogeneic HCT, prospective intensive sampling PK and PK-PD studies after subcutaneous alemtuzumab were conducted by our group in pediatric and young adult patients undergoing HCT